Replies to post #829 on Idenix Pharmaceuticals (IDIX)

[go seek]

lot of moving parts here... still think market has discounted NM283 to no value. While many HCV clinicians tout it's efficacy. We are moving towards new HCV combination trials / therapies

Certainly the VX data is important here but most say one drug will not take all.

think all classes will be represented in a new SoC and then perhaps riba can be dropped...